TrialThe Lancet. Oncology2014
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Karim Fizazi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
60 papers cite it
this paperpooled ittrialcites it